Volixibat

Research use only, not for human use.

A highly potent and selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) in development for the treatment of nonalcoholic steatohepatitis (NASH).

A highly potent and selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) in development for the treatment of nonalcoholic steatohepatitis (NASH).Steatohepatitis Phase 2 Clinical.

——

Volixibat (SHP626) (5-30 mg/kg; food intake; daily for 24 weeks) improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. Animal Model:Male Ldlr-/-.Leiden mice (high-fat diet, HFD)Dosage:5, 15, or 30 mg/kg Administration:Food intake; daily for 24 weeks.Result:Significantly increased the total amount of bile acid in feces. Significantly attenuated the HFD-induced increase in hepatocyte hypertrophy, hepatic triglyceride and cholesteryl ester levels, and mesenteric white adipose tissue deposition at the highest dose. Non-alcoholic fatty liver disease activity score (NAS) was significantly lower in volixibat-treated mice than in the HFD controls.

SHP-626 | SAR-548304 | LUM-002

Membrane Transporter/Ion Channel

ASBT Transporter

ASBT Transporter

Other Indications

Steatohepatitis

1025216-57-2

805.96

C38H51N3O12S2

>98% (HPLC)

——

O=C(NC1=CC=CC([C@H](C2=CC(N(C)C)=CC=C23)[C@@H](O)[C@](CC)(CCCC)CS3(=O)=O)=C1)N[C@H]4[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(O)=O)O4)O)OCC5=CC=CC=C5)O

N-[3-[(3S,4R,5R)-3-Butyl-7-(dimethylamino)-3-ethyl-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenyl]-N'-[3-O-(phenylmethyl)-6-O-sulfo-β-D-glucopyranosyl]urea

(-20℃)

With Ice Pack

≥ 2 years